Nivalis Therapeutics, Inc. NVLS
No live quote for NVLS yet.
Analyst view
Consensus: hold
Hold
Price target (mean) —
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 0.00 | 0.00 – 0.00 | 0.79 | 0.0% | 349.15M | -0.3% | 0 |
| Next quarter | 0.00 | 0.00 – 0.00 | 0.72 | 0.0% | 336.53M | +9.7% | 0 |
| Current year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 1.32B | -2.2% | 0 |
| Next year | 0.00 | 0.00 – 0.00 | 0.00 | 0.0% | 1.40B | +5.8% | 0 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 28, 2016 | Raymond James | Downgrade | — | Market Perform |
| Nov 28, 2016 | Cowen & Co. | Downgrade | — | Market Perform |
| Nov 28, 2016 | Baird | Downgrade | — | Neutral |
| Nov 28, 2016 | Stifel Nicolaus | Downgrade | — | Hold |
| Sep 12, 2016 | Raymond James | Initiated | — | Outperform |
| Jul 12, 2015 | Stifel Nicolaus | Initiated | — | Buy |
| Jul 12, 2015 | Cowen & Co. | Initiated | — | Outperform |
| Jul 12, 2015 | Baird | Initiated | — | Outperform |
| Jul 12, 2015 | H.C. Wainwright | Initiated | — | Buy |
| May 15, 2012 | JP Morgan | Downgrade | — | Underweight |